Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 5 | 6 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 5 | 7 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 4 | 5 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 9 | 10 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 5 | 5 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell Rep. 2025 Jan 28; 44(1):115156.
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024 Aug 08; 187(16):4373-4388.e15.
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
-
Integration of ?-deficient CARs into the CD3? gene conveys potent cytotoxicity in T and NK cells. Blood. 2024 06 20; 143(25):2599-2611.
-
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024 01 02; 15(1):89.
-
Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies. Iran J Immunol. 2023 12 31; 20(4):410-426.
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.